Lynx Advisors Pty Ltd’s Post

🎉Big news for Control Bionics! We're excited to announce our exclusive distribution agreement with Smartbox Assistive Technology, the UK’s leading assistive technology provider! This partnership allows us to expand the reach of our innovative NeuroNode® device into the UK and Ireland, empowering people with Motor Neurone Disease (#MND), cerebral palsy, and other neurological disorders. Key highlights: ✅ Exclusive distribution by Smartbox Ltd. ✅ Access to Smartbox’s strong network of healthcare professionals. ✅ Strengthened presence in the European market. We’re confident this partnership will accelerate the adoption of NeuroNode® and improve the quality of life for countless individuals with speech and motor impairments. 💪 #ControlBionics #NeuroNode #AssistiveTechnology #Smartbox #CerebralPalsy #Innovation #UK #Ireland Jeremy Steele Roger Hawke Peter S Ford David Falk Lindsay Phillips Joe Durak Kanak Sahasrabudhe Adi Deshpande

Our very own Jeremy Steele recently sat down with #AusbizTV to discuss the impact of our significant strategic milestone - US government approval for a new insurance code. This approval means our NeuroNode can now reach more people across the US, with coverage potential from Medicare, Medicaid, and even private insurance. It’s a significant step forward, ensuring that those who need our technology most can access it more easily. As Jeremy explained during the interview, getting a device approved for Medicare and Medicaid is no small feat—it’s a process that can take years. This is a huge achievement for Control Bionics, and we couldn't be more excited about the possibilities it opens up for the future! 🎥 Watch the full interview here https://lnkd.in/g3q8Kxaj #ControlBionics #MedTech #NeuroNode #Innovation #HealthcareTech #Medicare #Medicaid #AssistiveTechnology Roger Hawke Peter S Ford David Falk Lindsay Phillips Kerry Series Joe Durak Kanak Sahasrabudhe Adi Deshpande

📢  We’re thrilled to announce a significant strategic milestone with the approval of a new US Insurance Code Approved for our flagship technology, the NeuroNode®. This pivotal approval means the NeuroNode® is now officially recognised as a reimbursable medical device in the US, opening doors to a US$4,300 reimbursement that was previously unavailable. What does this mean? Once this becomes effective on 1 October 2024: 🌟 It results in a material benefit to the business’ operations in the US. 🌟 Represents a substantial opportunity to expand our wholesale distribution model as part of our ‘NeuroNode® Only’ strategy. 🌟 Both Control Bionics and our US partners will be able to apply for this reimbursement for customers covered by Medicare and Medicaid, and we’ll also work to have it covered ‘in-network’ with private insurers. This milestone accelerates our growth trajectory and strengthens our commitment to improving lives through innovative assistive technology. We look forward to the opportunities this new approval will bring! Roger Hawke Jeremy Steele Peter S Ford David Falk Kerry Series Lindsay Phillips Joe Durak Kanak Sahasrabudhe Adi Deshpande #ControlBionics #NeuroNode #ASX #HealthcareInnovation #MedTech #Medicare #Medicaid #USHealthcare #AssistiveTechnology